Managing IP Finds Bill Lee Among Top 10 Litigators in Life Sciences Patent Industry

Managing IP Finds Bill Lee Among Top 10 Litigators in Life Sciences Patent Industry

Attorney News
The June 2012 issue of Managing IP magazine includes Partner and Former Co-Managing Partner Bill Lee as one of only 10 individuals to be named as a top litigator in the Life Sciences Patent industry in the United States. This recognition comes not long after being selected as one of eight finalists in the The American Lawyer’s “Litigator of the Year” contest in January 2012.

Lee has tried more than 100 patent cases, both jury and jury waived, to judgment and argued more than 50 appeals before the Court of Appeals for the Federal Circuit and other courts of appeals. His recent life sciences clients include Abbott Laboratories, for whom he obtained a significant victory in the United States Court of Appeals for the Federal Circuit with the complete reversal of a $1.67 billion patent-infringement verdict; and Nycomed GmbH and Wyeth, on behalf of whom Lee achieved a jury verdict in the United States District Court for the District of New Jersey upholding the validity of a patent covering the active ingredient in the blockbuster gastric acid disorder treatment PROTONIX in the face of a challenge by companies that had launched generic versions of the drug before patent expiration.

The selection of Managing IP’s “Top 10” litigators is based off of the research conducted for the recently announced LMG Life Sciences 2012 directory, in which the firm was found to be “highly recommended” for general patent litigation and as “recommended” for Hatch-Waxman patent litigation.

For more information on Managing IP magazine, click here.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.